

Accepted Manuscript

Title: Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?

Author: Catherine J. Lee, Bipin N. Savani, Per Ljungman


PII: S1083-8791(18)30183-6
DOI: <https://doi.org/10.1016/j.bbmt.2018.04.003>
Reference: YBBMT 55087

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 2-3-2018
Accepted date: 3-4-2018

Please cite this article as: Catherine J. Lee, Bipin N. Savani, Per Ljungman, Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?, *Biology of Blood and Marrow Transplantation* (2018), <https://doi.org/10.1016/j.bbmt.2018.04.003>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?

Catherine J. Lee¹, Bipin N. Savani², Per Ljungman^{3,4}

¹Utah Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

²Vanderbilt University Medical Center, Nashville, TN, USA

³Department of Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

⁴ Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

Running title: VZV Reactivation in HCT Survivors

Key words: Varicella zoster virus; herpes zoster; prevention; vaccines; hematopoietic cell transplantation

Word Counts: Word Count-2,402; references- 32; table- 1; figure- 1

Correspondence:

Catherine J. Lee, MD; Utah Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 2152. Salt Lake City, UT, USA, 84103. Tel: +1-801-587-0231; Fax: +1-801-581-4136; Email: Catherine.lee@hci.utah.edu

Author Contributions: Catherine Lee: Conceptualization and writing - original draft, and writing – review and editing. Bipin Savani: writing - review and editing. Per Ljungman: writing – review and editing.

All authors guarantee the content of this manuscript.

Conflict of interest/ disclosures: None from all authors

Funding: None

HIGHLIGHTS

- Survivors of hematopoietic cell transplantation (HCT) are at increased risk of varicella zoster virus (VZV) reactivation.
- Prolonged antiviral prophylaxis with acyclovir or valacyclovir remains the standard preventive measure against VZV reactivation although it remains unclear when it can be stopped.

Download English Version:

<https://daneshyari.com/en/article/10157446>

Download Persian Version:

<https://daneshyari.com/article/10157446>

[Daneshyari.com](https://daneshyari.com)